477 related articles for article (PubMed ID: 33130441)
21. A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma.
Ni W; Yu S; Zhang W; Xiao Z; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Gao S; Mao Y; Xue Q; Sun K; Liu X; Fang D; Li J; Wang D
BMC Cancer; 2020 Feb; 20(1):130. PubMed ID: 32070309
[TBL] [Abstract][Full Text] [Related]
22. Does Neutrophil-to-Lymphocyte Ratio (NLR) Predict Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma?
Anand S; Bhati G; Gurram R; Gnanasekaran S; Kate V; Pottakkat B; Kalayarasan R
J Gastrointest Cancer; 2021 Jun; 52(2):659-665. PubMed ID: 32607960
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the 7th edition of the TNM classification in patients with resected esophageal squamous cell carcinoma.
Wang J; Wu N; Zheng QF; Yan S; Lv C; Li SL; Yang Y
World J Gastroenterol; 2014 Dec; 20(48):18397-403. PubMed ID: 25561808
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of visual residual tumour cells (VRTC) for patients with esophageal squamous cell carcinomas after neoadjuvant therapy followed by surgery.
Wang X; Wang H; Wang H; Huang J; Wang X; Jiang Z; Tan L; Jiang D; Hou Y
BMC Cancer; 2021 Feb; 21(1):111. PubMed ID: 33535987
[TBL] [Abstract][Full Text] [Related]
25. Clinical Implications of Conversion Surgery After Induction Therapy for T4b Thoracic Esophageal Squamous Cell Carcinoma.
Miyata H; Sugimura K; Motoori M; Omori T; Yamamoto K; Yanagimoto Y; Shinno N; Yasui M; Takahashi H; Wada H; Ohue M; Yano M
Ann Surg Oncol; 2019 Dec; 26(13):4737-4743. PubMed ID: 31414291
[TBL] [Abstract][Full Text] [Related]
26. PATHOLOGIC COMPLETE RESPONSE (YPT0 YPN0) AFTER CHEMOTHERAPY AND RADIOTHERAPY NEOADJUVANT FOLLOWED BY ESOPHAGECTOMY IN THE SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS.
Andreollo NA; Beraldo GC; Alves IPF; Tercioti-Junior V; Ferrer JAP; Coelho-Neto JS; Lopes LR
Arq Bras Cir Dig; 2018 Dec; 31(4):e1405. PubMed ID: 30539980
[TBL] [Abstract][Full Text] [Related]
27. Modified ypTNM Staging Classification for Gastric Cancer after Neoadjuvant Therapy: A Multi-Institutional Study.
Zhong Q; Chen QY; Parisi A; Ma YB; Lin GT; Desiderio J; Yan S; Xie JW; Wang JB; Hou JF; Lin JX; Lu J; Cao LL; Lin M; Tu RH; Huang ZN; Lin JL; Liu ZY; Que SJ; Li P; Zheng CH; Huang CM
Oncologist; 2021 Jan; 26(1):e99-e110. PubMed ID: 32864840
[TBL] [Abstract][Full Text] [Related]
28. Minimal invasive versus open esophagectomy for patients with esophageal squamous cell carcinoma after neoadjuvant treatments.
Chen D; Wang W; Mo J; Ren Q; Miao H; Chen Y; Wen Z
BMC Cancer; 2021 Feb; 21(1):145. PubMed ID: 33563244
[TBL] [Abstract][Full Text] [Related]
29. Interval between neoadjuvant chemoradiotherapy and surgery for esophageal squamous cell carcinoma: does delayed surgery impact outcome?
Chiu CH; Chao YK; Chang HK; Tseng CK; Chan SC; Liu YH; Chen WH
Ann Surg Oncol; 2013 Dec; 20(13):4245-51. PubMed ID: 23959050
[TBL] [Abstract][Full Text] [Related]
30. Application of the 8th edition of the AJCC yTNM staging system shows improved prognostication in a single center cohort of esophageal carcinomas.
Kröll D; Noser L; Erdem S; Storni F; Arnold D; Dislich B; Zlobec I; Candinas D; Seiler CA; Langer R
Surg Oncol; 2018 Mar; 27(1):100-105. PubMed ID: 29549896
[TBL] [Abstract][Full Text] [Related]
31. Impact of perineural invasion as a histopathological prognostic factor in ypStage II/III oesophageal squamous cell carcinoma†.
Hsu PK; Chien LI; Lin CH; Yeh YC; Chuang CY; Hsu HS; Wu YC; Hsu CP
Eur J Cardiothorac Surg; 2019 May; 55(5):927-933. PubMed ID: 30496377
[TBL] [Abstract][Full Text] [Related]
32. Optimal Time-to-Surgery Recommendations Based on Primary Tumor Volume Regression for Patients with Resectable Esophageal Cancer after Neoadjuvant Chemoradiotherapy: A Retrospective Study.
Li J; Zhou X; Liu Y; Zhu J; Wan G; Wang Y; Leng X; Han Y; Peng L; Wu L; Wang Q
Ann Surg Oncol; 2024 Jun; 31(6):3803-3812. PubMed ID: 38280959
[TBL] [Abstract][Full Text] [Related]
33. Proposal of New ypStage Grouping System for Esophageal Squamous Cell Carcinoma Patients who Underwent Neoadjuvant Chemoradiotherapy followed by Surgery.
Park SY; Park B; Yun JK; Kim HR; Kim YH; Jeon YJ; Lee J; Cho JH; Choi YS; Zo JI; Shim YM; Kim HK
Ann Surg; 2024 Jan; ():. PubMed ID: 38230528
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma.
Sasaki K; Uchikado Y; Omoto I; Arigami T; Osako Y; Noda M; Okumura H; Maemura K; Higashi R; Yoshiura T; Natsugoe S
Cancer Chemother Pharmacol; 2019 Mar; 83(3):581-587. PubMed ID: 30623230
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China.
Zhang G; Zhang C; Sun N; Xue L; Yang Z; Fang L; Zhang Z; Luo Y; Gao S; Xue Q; Mu J; Gao Y; Tan F; He J
J Cancer Res Clin Oncol; 2022 Apr; 148(4):943-954. PubMed ID: 34013382
[TBL] [Abstract][Full Text] [Related]
36. Perineural invasion through the sheath in posttherapy esophagectomy specimens predicts poor survival in patients with esophageal squamous cell carcinoma.
Tsai CY; Yeh CJ; Chao YK; Chang HK; Tseng CK; Liu YH
Eur J Surg Oncol; 2017 Oct; 43(10):1970-1976. PubMed ID: 28801062
[TBL] [Abstract][Full Text] [Related]
37. The Prognostic Value of the AJCC 8th Edition Staging System for Patients Undergoing Neoadjuvant Chemotherapy for Breast Cancer.
Kantor O; Bao J; Jaskowiak N; Yao K; Tseng J
Ann Surg Oncol; 2020 Feb; 27(2):352-358. PubMed ID: 31376037
[TBL] [Abstract][Full Text] [Related]
38. Pathological stage after neoadjuvant chemoradiation and esophagectomy superiorly predicts survival in patients with esophageal squamous cell carcinoma.
Wang CC; Cheng JC; Tsai CL; Lee JM; Huang PM; Lin CC; Hsu CH; Hsieh MS; Chang YL; Hsu FM
Radiother Oncol; 2015 Apr; 115(1):9-15. PubMed ID: 25819996
[TBL] [Abstract][Full Text] [Related]
39. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study.
Gong L; Mao W; Chen Q; Jiang Y; Fan Y
Cancer Chemother Pharmacol; 2019 Apr; 83(4):639-647. PubMed ID: 30643929
[TBL] [Abstract][Full Text] [Related]
40. Prognostic impact of the 6th and 7th American Joint Committee on Cancer TNM staging systems on esophageal cancer patients treated with chemoradiotherapy.
Nomura M; Shitara K; Kodaira T; Hatooka S; Mizota A; Kondoh C; Yokota T; Takahari D; Ura T; Muro K
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):946-52. PubMed ID: 21362578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
